Navigation Links
Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
Date:5/25/2011

Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.

Results of a study of 1032 patients with early (less than one year), active RA initially assessed response to treatment after 26 weeks with ADA 40mg every other week + MTX versus MTX alone. Results show that 44% of patients treated with the combination therapy achieved the target of sustained low disease activity at week 26, versus 24% of those treated with MTX alone. Patients reaching the target on ADA+MTX were considered responders and then further randomised to continue or withdraw from treatment with ADA 40mg every other week.

Patients who continued treatment maintained good clinical, radiographic and functional responses through to week 78, including a high proportion achieving higher measures of disease control. 77% achieved ACR70*, 86% reached DAS remission (DAS28≤2.6**) and 89% had no radiographic progression***. Interestingly, the majority of patients who had treatment withdrawn also showed good outcomes: 65% and 66% achieved ACR70 response and DAS28≤2.6**, respectively, and 81% showed no radiographic progression. The results in those patients discontinuing ADA indicate that it may be possible to withdraw ADA treatment in specific patients, without impacting long term patient outcomes.

"Data from the OPTIMA study has confirmed previous studies in showing that initial and continued adalimumab treatment in early RA can ensure that higher levels of disease control can be achieved and maintained," said Professor Paul Emery, Leeds Teaching Hospital, Leeds, England, and EULAR President. "Importantly, results of this first global study assessing biologic free disease control demonstrate that it may be possible to successfully withdraw anti-TNF therapy in certain patients and maintain long term positive outcomes although further studies in this area are needed."

Safety findings over the whole study period were generally similar to the profile seen with anti-TNF treatments in the treatment of active RA. Adverse events were evaluated for 850 patients who received ADA: serious adverse events included 9 deaths (1.0 per 100 patient years (/100PY)), 39 serious infections (4.4/100PY); 11 malignancies (1.2/100PY) including 5 non-melanoma skin cancers (0.6/100PY); 8 opportunistic infections (excluding tuberculosis) (0.9/100PY); with 4 confirmed as tuberculosis (0.5/100PY).


'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related biology news :

1. On the trail of a targeted therapy for blood cancers
2. Cellular discovery may lead to targeted treatment for rare form of anemia
3. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
4. Targeted drug therapy prevents exercise-induced arrhythmias
5. Breakthrough in radiotherapy promises targeted cancer treatment
6. Genetic finding could lead to targeted therapy for neuroblastoma
7. New subtype of breast cancer responds to targeted drug
8. Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles
9. UC to test targeted treatment for prostate cancer
10. New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
11. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: